Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin

What Was Tested

This controlled clinical trial paper looks at Somatostatin in the context of psoriasis and psoriatic arthritis.

This study presents an immunohistochemical characterization of somatostatin-positive dendritic cells in psoriatic lesions.

Somatostatin is a neuropeptide with inhibitory action on several neuropeptides and hormones, but also with immunomodulating properties, and has been used in several studies as treatment for psoriasis.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a double-blind study.

As a double-blind Somatostatin study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Biopsy, Cells, Cultured, Dendritic Cells, HLA-DR Antigens, Hormone Antagonists and Immunohistochemistry.

What This Means in Plain Language

The paper is a double-blind study of Somatostatin in people with psoriasis and psoriatic arthritis.

The publication is from 1997 (Acta dermato-venereologica), a journal based in Sweden.

More context: the Somatostatin compound page, Psoriasis and psoriatic arthritis research.